SCHOTT Pharma KGaA has delivered a 73.2% year to date return, which raises the question of whether the current share price is still backed by the cash the business is expected to generate over time. For anyone looking at the stock today, the key issue is how that market enthusiasm lines up with what a Discounted Cash Flow (DCF) view of its future cash flows suggests.
-
The 73.2% gain year to date puts significant focus on the idea that SCHOTT Pharma KGaA can maintain or improve the cash it generates from its operations.
-
The company's profile in drug delivery and pharmaceutical solutions can influence expectations for how reliably it converts revenue into free cash flow, and how much reinvestment it may need to support that cash flow.
-
If you'd rather focus on earnings, this one's for you. See why SCHOTT Pharma KGaA's 28.2x P/E tells a different valuation story .
The key question is whether the stock's recent performance aligns with the intrinsic value indicated by its cash flows under a Discounted Cash Flow (DCF) assessment.
If you want a broader watchlist of cash flow driven ideas to research alongside SCHOTT Pharma KGaA, start with 201 high quality undervalued stocks .
Is SCHOTT Pharma KGaA Fairly Priced on Cash Flow?
The Discounted Cash Flow (DCF) approach here projects what SCHOTT Pharma KGaA could return to shareholders in future and then brings those amounts back into today's money. Over the last twelve months the business generated roughly €33.4 million of free cash flow, and the model assumes this builds over time rather than contracts.
Analyst projections in the DCF point to higher annual free cash flow levels in the coming decade, with later years based on more moderate estimates once those forecasts run out. With the current share price at €25.50, the outcome of this cash flow profile is that the Discounted Cash Flow (DCF) projections put SCHOTT Pharma KGaA's estimated intrinsic value broadly in line with the current share price. Find out what SCHOTT Pharma KGaA could be worth using our Discounted Cash Flow (DCF) estimate .
The SCHOTT Pharma KGaA Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the DCF leaves off and explain which combinations of growth, margins and earnings would need to hold for SCHOTT Pharma KGaA's share price to end up materially above or below where it trades today. Each narrative links a fair value estimate to a particular set of catalysts and risks for SCHOTT Pharma KGaA's business so you can observe over time which version of the story appears to be taking shape in the real world.
Community views on SCHOTT Pharma KGaA are split between those who see further potential from high value solutions and those who think the bar is already high.
Bull case: 6% undervalued
"Faster than previously guided mix shift into high-value solutions, with HVS already contributing close to 60% of revenue and DCS HVS share rising…"
Discover why this Narrative puts SCHOTT Pharma KGaA at 6% undervalued .
Bear case: 7% overvalued
"Pressure in Drug Delivery Systems, where revenue in the first nine months of 2026 was flat at €325.1 million and the EBITDA margin moved from 35.1% to 29.4%…"
Explore why this Narrative puts SCHOTT Pharma KGaA at 7% overvalued .
For SCHOTT Pharma KGaA, who steers the ship may matter as much as what it is worth
Before you stop at the numbers, it is worth asking who is actually steering SCHOTT Pharma KGaA and how their pay packets line up with your interests. See who runs SCHOTT Pharma KGaA and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 1SXP.DE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
